CA2292899A1 - Element ntn-2 de la famille des ligands du tnf - Google Patents

Element ntn-2 de la famille des ligands du tnf Download PDF

Info

Publication number
CA2292899A1
CA2292899A1 CA002292899A CA2292899A CA2292899A1 CA 2292899 A1 CA2292899 A1 CA 2292899A1 CA 002292899 A CA002292899 A CA 002292899A CA 2292899 A CA2292899 A CA 2292899A CA 2292899 A1 CA2292899 A1 CA 2292899A1
Authority
CA
Canada
Prior art keywords
human ntn
human
ntn
polypeptide
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002292899A
Other languages
English (en)
Inventor
Piotr Masiakowski
David Valenzuela
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/US1998/011153 external-priority patent/WO1998055620A1/fr
Publication of CA2292899A1 publication Critical patent/CA2292899A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Cette invention se rapporte aux polypeptides dits "NTN-2 HUMAIN" et à leurs acides nucléiques associés. Elle se rapporte aux polypeptides NTN-2 HUMAINS comportant un domaine NTN-2 HUMAIN possédant une activité spécifique de NTN-2 HUMAIN. Il est possible de produire ces polypeptides par recombinaison à partir de cellules hôtes transformées en utilisant les acides nucléiques de la présente invention. Cette invention se rapporte également à des agents de liaison spécifiques et à des procédés de fabrication et d'utilisation de compositions contenant ces polypeptides.
CA002292899A 1997-06-06 1998-06-03 Element ntn-2 de la famille des ligands du tnf Abandoned CA2292899A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4877697P 1997-06-06 1997-06-06
US60/048,776 1997-06-06
US6638797P 1997-11-21 1997-11-21
US60/066,387 1997-11-21
PCT/US1998/011153 WO1998055620A1 (fr) 1997-06-06 1998-06-03 Element ntn-2 de la famille des ligands du tnf

Publications (1)

Publication Number Publication Date
CA2292899A1 true CA2292899A1 (fr) 1998-12-10

Family

ID=26726521

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002292899A Abandoned CA2292899A1 (fr) 1997-06-06 1998-06-03 Element ntn-2 de la famille des ligands du tnf
CA002292835A Abandoned CA2292835A1 (fr) 1997-06-06 1998-06-03 Membre ntn-2 de la famille des ligands du facteur de necrose tumorale (tnf)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002292835A Abandoned CA2292835A1 (fr) 1997-06-06 1998-06-03 Membre ntn-2 de la famille des ligands du facteur de necrose tumorale (tnf)

Country Status (6)

Country Link
EP (1) EP0991759A1 (fr)
JP (1) JP2002517977A (fr)
AU (1) AU7608898A (fr)
CA (2) CA2292899A1 (fr)
IL (1) IL133316A0 (fr)
WO (1) WO1998055621A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689579B1 (en) 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
WO1999011791A2 (fr) * 1997-09-05 1999-03-11 University Of Washington Recepteurs et ligands de la famille du facteur de necrose tumorale, acides nucleiques codants et agents de liaison associes
WO1999026463A2 (fr) * 1997-11-26 1999-06-03 Eli Lilly And Company Gene de la famille des ligand tnf
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
AU2093499A (en) * 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
WO2000026244A2 (fr) * 1998-11-04 2000-05-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nouveau membre de la famille des facteurs de necrose des tumeurs, ligand du recepteur de la mort cellulaire (drl) et compositions et procedes correspondants
GB9828628D0 (en) * 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
PT1642972E (pt) * 1999-01-07 2010-04-07 Zymogenetics Inc Utilizações terapêuticas de receptores solúveis br43x2
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
DK1146892T3 (da) 1999-01-25 2003-11-24 Apoxis Sa BAFF, inhibitorer deraf og deres anvendelse i modulationen af B-celle responset
US6475986B1 (en) * 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
WO2000047740A2 (fr) * 1999-02-12 2000-08-17 Amgen Inc. Proteines associees au facteur de necrose des tumeurs
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
IL148089A0 (en) 1999-08-17 2002-09-12 Biogen Inc Baff receptor (bcma), an immunorgulatory agent
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
AU2001261557B2 (en) 2000-05-12 2005-06-30 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
WO2002002641A1 (fr) 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Anticorps se liant de maniere immunospecifique a un stimulateur de lymphocyte b
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
EE05294B1 (et) 2001-05-11 2010-04-15 Amgen Inc. TALL-1-ga seostuv ainekompositsioon
ATE542545T1 (de) 2001-05-24 2012-02-15 Zymogenetics Inc Taci-immunoglobulin-fusionsproteine
NZ543174A (en) 2003-03-28 2008-09-26 Biogen Idec Inc Truncated BAFF receptors
WO2005051994A2 (fr) * 2003-11-21 2005-06-09 Zymogenetics, Inc. Facteur de necrose tumorale ztnf11
EP2332563A3 (fr) * 2004-10-13 2013-03-13 The Washington University Utilisation de BAFF pour traiter la sepsie
EA016083B1 (ru) 2005-08-09 2012-02-28 Займоджинетикс, Инк. СПОСОБ ЛЕЧЕНИЯ НЕХОДЖКИНСКОЙ ЛИМФОМЫ С ПОМОЩЬЮ СЛИТОЙ МОЛЕКУЛЫ TACI-Ig
WO2007019573A2 (fr) 2005-08-09 2007-02-15 Zymogenetics, Inc. Procedes pour le traitement et la prevention de proliferation cellulaire anormale par le biais de molecules de fusion taci
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
JP6088723B2 (ja) 2005-11-23 2017-03-01 ジェネンテック， インコーポレイテッド Ｂ細胞アッセイに関する組成物及び方法。
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
CN101489573B (zh) 2006-05-15 2013-05-22 阿雷斯贸易股份有限公司 用TACI-Ig融合分子治疗自身免疫疾病的方法
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
CN106367714A (zh) 2015-07-24 2017-02-01 先健科技(深圳)有限公司 铁基可吸收植入医疗器械与预制管及其制备方法
WO2018115879A1 (fr) 2016-12-21 2018-06-28 Mereo Biopharma 3 Limited Utilisation d'anticorps anti-sclérostine dans le traitement de l'ostéogenèse imparfaite

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE302272T1 (de) * 1996-10-25 2005-09-15 Human Genome Sciences Inc Neutrokin alpha
AU5705898A (en) * 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents

Also Published As

Publication number Publication date
JP2002517977A (ja) 2002-06-18
EP0991759A1 (fr) 2000-04-12
CA2292835A1 (fr) 1998-12-10
AU7608898A (en) 1998-12-21
WO1998055621A1 (fr) 1998-12-10
IL133316A0 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
AU743490B2 (en) NTN-2 member of TNF ligand family
CA2292899A1 (fr) Element ntn-2 de la famille des ligands du tnf
US6475987B1 (en) Tall-1 receptor homologues
BG65519B1 (bg) Белтъци, свързващи интерлевкин-18, тяхното получаване и приложение
EP1019502A2 (fr) Nouveau recepteur orphelin
AU9230398A (en) Cysteine rich receptors-train
US20020160451A1 (en) Novel orphan receptors
AU748167B2 (en) Novel nucleic acid and polypeptide
AU2675197A (en) Novel protein - traf6
CA2339968A1 (fr) Dcr5, proteine de fixation de proteines morphogenetiques osseuses, et ses applications
WO2000018800A1 (fr) Nouvelles proteines secretees immunomodulatrices et leurs applications
WO1999026980A1 (fr) Reactifs et procedes d'utilisation de proteines de la famille sap, nouveaux regulateurs de transduction de signaux
AU753400C (en) Orphan receptors
US6207413B1 (en) Nucleic acids encoding novel orphan cytokine receptors
JPH1072495A (ja) 免疫関連因子

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20040603